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Abstract
Background Marijuana is legal in a number of states for indications that include inflammatory bowel diseases (IBD), and 
patients are interested in its potential benefits.
Aims We aimed to describe the legal use of marijuana in individuals with IBD in the USA who participate within the CCFA 
Partners internet-based cohort.
Methods A total of 2357 participants who lived in states where prescription or recreational marijuana was legal, were offered 
the opportunity to complete a survey on marijuana use and IBD symptoms including perceived benefits of therapy. Bivariate 
statistics and logistic regression models were used to determine factors associated with marijuana use.
Results Surveys were completed by 1666 participants (71%) with only 214 (12.8%) indicating they had asked their medi-
cal doctor about its use and 73 actually using prescribed marijuana (4.4%). Within the respondent group (N = 1666), 234 
participants lived where both medical and recreational marijuana is legal and 49 (20.9%) reported recreational marijuana 
use specifically for IBD. Users reported positive benefits (80.7%), but users also reported more depression, anxiety, pain 
interference, and lower social satisfaction than non-users. Those prescribed marijuana reported more active disease, and 
more use of steroids, narcotics, and zolpidem.
Conclusions Few IBD patients consulted their medical doctors about marijuana use or used prescription marijuana. Where 
recreational marijuana was available, usage rates were higher. Users reported benefits but also more IBD symptoms, depres-
sion, anxiety, and pain. Marijuana use may be higher in patients with IBD symptoms not well treated by conventional medical 
approaches.
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic 
inflammatory bowel diseases (IBD) that significantly impair 
quality of life. There are increasing numbers of options for 
medical treatment of inflammation, including novel classes 
of immunosuppressive and biologic therapies [1]. However, 
symptoms can remain despite treatment. Many patients have 
an interest in alternative therapies due to concerns about 
risks or side effects of medications, or as a supplement to 
standard treatment protocols. For these reasons, there has 
been interest in the patient and provider communities in 
understanding the role of marijuana in IBD.
A review of the literature conducted in 2015 concluded 
that more research was needed to determine whether there 
were any medical benefits of marijuana [2]. Both epidemio-
logic data and small trials demonstrate a possible role for 
cannabinoids in the symptomatic treatment of IBD. As of 
yet, it is unclear whether these therapies have anti-inflam-
matory effects, or whether they are masking the debilitating 
symptoms of ongoing inflammation in IBD [3].
A number of published studies suggest that patients 
with IBD who use marijuana can derive symptomatic 
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benefits [4–7]. It is also apparent that a large number of 
IBD patients have tried marijuana, particularly older men 
[8]. There are limited data on the characteristics of mari-
juana users in the IBD population. In particular, further 
information is needed on disease activity, concomitant 
psychosocial factors, and whether IBD medications are 
also used by this population.
To learn more about the use of marijuana in the USA, 
we developed a survey to ascertain the characteristics of 
marijuana users in states where marijuana is legal by pre-
scription or for recreational use. We hypothesized that 
few IBD patients would have access to prescribed mari-
juana, and we were interested in learning what benefits 
those using prescription or recreational marijuana might 
perceive.
Materials and Methods
CCFA Partners is a longitudinal, internet-based cohort of 
self-identified adult IBD patients [9] including nearly 15,000 
patients who completed a baseline health survey and provide 
updates every 6 months. The present study was made avail-
able to patients residing in 25 states where prescription mari-
juana is legal; 4 of these states also legalized recreational 
marijuana use. The survey (see supplementary Fig. 1) was 
offered to 2357 participants over an 8-month time period. Of 
these, 1666 actually completed the survey (65.7% response 
rate) and are included in the analysis.
We measured disease activity using the Short Crohn’s 
Disease Activity Index; an sCDAI of less than 150 was 
defined as remission [10]. Using the Simple Clinical Colitis 
Activity Index (SCCAI) for ulcerative colitis or indetermi-
nate colitis (UC/IC), remission was defined as an SCCAI of 
2 or less [11].
The Short Inflammatory Bowel Disease Questionnaire 
(SIBDQ) is a measure of health-related quality of life that 
has been validated for use in IBD patients [12]. It consists 
of 10 questions rated on a seven-point Likert scale, with 
a test–retest reliability coefficient established at 0.65, and 
Cronbach’s alpha at 0.78 [12]. The higher the SIBDQ score, 
the better the measured quality of life (QOL).
We used several  PROMIS® instruments to measure 
anxiety, depression, pain, sleep, and social satisfaction. 
 PROMIS® (Patient-Reported Outcomes Measurement 
Information System) instruments have undergone rigorous 
development and validation [13]. They are calibrated using 
a T-score metric with the mean of the US general popula-
tion equal to 50 and SD equal to 10. Minimal important 
differences (MIDs) of these PROMIS domains for chronic 
diseases are in the range of 2–6 [14, 15]. Higher scores indi-
cate more of the domain being measured.
Statistical Analysis
All analyses were performed using SAS version 9.3 (SAS 
Institute, Cary, NC). Categorical variables were compared 
using Chi-square statistics. Continuous variables were com-
pared using t tests or Wilcoxon rank-sum test as appropri-
ate. For PROMIS domains, measures were dichotomously 
defined as PROMIS t scores ≥ 55, as this one-half standard 
deviation difference met criteria for minimal important dif-
ferences. We used logistic regression modeling to deter-
mine independent predictors of marijuana use among IBD 
patients. Statistical significance was defined as a p value less 
than 0.05.
Ethical Considerations
Participants sign informed consent when they join the CCFA 
Partners cohort. The study was approved by the Institutional 
Review Board at the University of North Carolina.
Results
For participants living in states where medical marijuana 
was legal, only 214 participants (N = 1666, 12.8%) reported 
that they had asked their medical doctor about its use for 
IBD symptoms. Eighty-three participants were prescribed 
marijuana and 73 actually used the drug (4.4%). Among the 
1666 respondents, 234 lived in states where both medical 
and recreational marijuana were legal and 49 (20.9%) stated 
they used recreational marijuana specifically for their IBD. 
There were a total of 122 reports of legal marijuana use 
specifically for IBD; however, 8 participants reported both 
recreational and medical marijuana use, yielding a total of 
114 unique participant responses.
The majority of marijuana users in this survey (80.7%) 
perceived benefits of its use (presented in Table 1). These 
included improvement in pain (68%), appetite (49%), anxiety 
(48%), fatigue (26%), stool frequency (23%), weight gain 
(20%), and blood in stool (5%), and there were two write-in 
responses indicating benefit for nausea (1.8%). Twenty-two 
(19%) users indicated no symptom relief.
Results comparing those patients who used prescribed 
recreational marijuana (n = 114), compared to non-users 
(n = 1552), on the PROMIS measures are presented in 
Table 2. Overall, those using marijuana reported signifi-
cantly more anxiety, depression, pain, and lower social 
satisfaction.
We were interested in examining the characteristics of 
patients who were prescribed marijuana by their physicians 
to shed light on why physicians thought their patients might 
67.3% ever use of marijuana and hashish in IBD patients in 
a large population study [8], may be due to the fact that our 
survey was not anonymous, since participants are part of 
an ongoing longitudinal study. We also asked about legal 
marijuana use specifically for IBD, rather than any use ever.
When exploring the profiles of patients using marijuana, 
the majority stated it was helpful with symptoms (86%), 
particularly identifying its benefits for pain, appetite, and 
anxiety, followed by fatigue, weight gain, stool frequency, 
and blood in stool. Four other studies found similar results, 
especially identifying pain. Allegretti et al. [4] found that 
patients reported benefits for pain, appetite, nausea, and diar-
rhea (N  =  292). In a study by Storr et al. [7] (N = 303) mari-
juana was perceived helpful for abdominal pain, abdominal 
cramping, joint pain, and diarrhea, but patients had a higher 
risk of IBD surgery; our findings are similar. Lal et al. [6] 
(N = 191) found that pain, diarrhea, and appetite were the 
main symptom improvements reported. In a retrospective 
observational study, Naftali et al. [16] (N = 30) reported mul-
tiple benefits including objective markers of disease in male 
CD patients. All four studies, and ours, reveal somewhat 
different findings.
Two clinical trials were located in the literature. Naftali 
et al. [5] found a clinical response in 10/11 patients and full 
remission in 5 of those patients, when using smoked mari-
juana in their placebo-controlled clinical trial. Another pla-
cebo-controlled clinical trial (n = 65) by de Vries et al. [17] 
found no difference between placebos and orally ingested 
tablets containing tetrahydrocannabinol used for pain con-
trol. Some differences in methods of administration and dos-
ing may contribute to these conflicting results.
Because the medical marijuana users in our study 
reported more prior surgeries, and a poorer quality of health 
overall, it is conjectured that patients who are prescribed 
marijuana may have disease that is poorly controlled with 
conventional measures or that they may have significant 
symptoms that are not addressed by conventional therapies 
Table 1  Reported benefits of 
marijuana on IBD symptoms in 
CCFA partners among medical 
and recreational users
a 8 participants were in both prescribed and recreational categories
Symptom improvements Used by prescription 
(N = 73) n (%)
Used recreationally 
(N = 49) n (%)
Total unique 
 responsesa (N = 114) 
n (%)
Pain 56 (76.7) 27 (55.1) 78 (68.4)
Fatigue 18 (24.7) 15 (30.6) 30 (26.3)
Appetite 46 (63.0) 15 (30.6) 56 (49.1)
Anxiety 40 (54.8) 20 (40.8) 55 (48.2)
Weight gain 11 (15.1) 5 (10.2) 23 (20.2)
Stool frequency 19 (26.0) 5 (10.2) 23 (20.2)
Blood in stool 6 (8.2) 1 (2.0) 6 (5.3)
Other 21 (28.8) 10 (20.4) 30 (26.3)
Did not help 10 (13.7) 14 (8.6) 22 (19.3)
Table 2  PROMIS measures in IBD patients using/not using mari-
juana
PROMIS measures are reported using a T-score metric with the mean 
of the US general population equal to 50 and SD in the general popu-
lation equal to 10
a 73 patients used prescribed marijuana and 49 used recreational mari-
juana; 8 participants were in states where both prescribed and recrea-
tional marijuana are legal and are counted only once
benefit from its use. There were 83 who were given prescrip-
tions, and their characteristics are presented in Table 3. Most 
of the CD patients had active disease (57.4%), as did UC/IC 
patients (70.6%). Prescribed marijuana patients were also 
much more likely to have had IBD surgery (14.5 vs. 4.7%, 
p = 0.0008), report a lower quality of life on the SIBDQ 
(4.5 vs. 5.3; p = 0.0001), and were taking steroids (18.1 vs. 
10.4%, p = 0.04), narcotics (27.7 vs. 6.4%, p = 0.0001), and 
zolpidem, a prescription sleep aid (12.0 vs. 4.0%, p = 0.003). 
They were less likely to take aminosalicylates (22.9 vs. 
36.9%, p = .01).
Discussion
The number of CCFA Partners participants who reported 
being prescribed marijuana or using it specifically for 
IBD were few (n = 114, 6.8%), as we hypothesized. This 






Non-use (N = 1552)
Mean (SD)
p value
Anxiety 54.1 (9.8) 51.0 (9.2) < 0.0001
Depression 52.3 (9.8) 49.1 (8.7) < 0.0001
Pain interference 55.5 (10.4) 50.1 (9.5) < 0.0001
Sleep disturbance 52.3 (3.2) 52.1 (3.3) 0.30
Social satisfaction 48.0 (10.4) 50.9 (9.7) 0.0001
(such as visceral hypersensitivity), and more psychosocial 
comorbidities.
There have been recent studies that found positive effects 
of cannabis on IBD in animal studies [18–20], and articles 
demonstrating positive effects of cannabinoids at the molec-
ular level [21–24]. Cannabis can reduce cramping and slow 
GI motility [25]. Exogenous cannabinoids can also reduce 
colitis [25]. There are also questions in regard to the safety 
profile of marijuana, particularly in regard to dosing and 
route of administration to maximize benefits and reduce 
harms [26]. Physicians should be aware of the limited data 
supporting marijuana use and follow AMA guidelines and 
legal restrictions [26].
There are limitations to this study. We did not capture 
methods of administration or dosing, and this makes com-
parisons with other surveys problematic. We also do not 
have the time frame between when prescription marijuana 
users were diagnosed and when they began using marijuana, 
which might help determine its effects on the course of dis-
ease, for instance. Additionally, we did not capture perceived 
adverse events from marijuana use. Finally, the measures 
of disease activity used in CCFA Partners, while validated 
in self-report, are symptom-based. Therefore, we were 
unable to define disease activity through objective markers 
of inflammation, such as C-reactive protein or endoscopic 
measures of inflammation.
While legal marijuana use was limited in our survey, users 
perceived some benefit. Marijuana may be filling an unmet 
medical need for some patients. Ultimately, large-scale clini-
cal trials are needed to clarify mixed results found in the 
current literature.
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